

## AGENDA

*Uniform Formulary Beneficiary Advisory Panel  
27 September 2012 @ 0900 AM*

*Naval Heritage Center Theater  
701 Pennsylvania Ave. NW., Washington DC 20004*

- **Administrative Meeting (BAP members only @ 8:00 AM-9:00 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

*Members of the DoD Pharmacoeconomic Center will present relative clinical and cost effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.*

*The Committee made recommendations of the following drug classes during the Feb 2012 meeting:*

- **Drug Class Reviews:**
  - *Androgens Anabolic Steroids—Transdermal and Buccal Testosterone Replacement Therapies (TRT)*
  - *Anticoagulants—Heparin and Related Products Dipeptidyl Peptidase-4 (DPP-4) Inhibitors*
- **Designated Newly Approved Drugs:**
  - *Targeted Immunomodulatory Biologics (TIBs)—Abatacept subcutaneous injection (Orencia SC)*
  - *Glaucoma Drugs: Prostaglandin Analogs—Tafluprost ophthalmic solution (Zioptan)*
  - *Oral Non-steroidal Anti-inflammatory Drugs (NSAIDs)—Ibuprofen/famotidine tablets (Duexis)*
  - *Oral NSAIDs—Ketorolac Nasal Spray (Sprix)*
  - *Non-Insulin Diabetes Drugs: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors—Sitagliptin/metformin extended release (Janumet XR) and linagliptin/metformin (Jentadueto)*

:

➤ **Panel Discussions**

*The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.*